Business Context and Reporting Period
Company: Inotiv, Inc. (NOTV)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and six months ended March 31, 2025
Business Overview: Inotiv is a leading contract research organization (CRO) providing nonclinical and analytical drug discovery services (Discovery and Safety Assessment segment) and selling research-quality animals and diets (Research Models and Services segment). The company operates globally with significant exposure to non-human primate (NHP) supply chains.
Key Financial Metrics
| Metric (in thousands) | Three Months Ended March 31, 2025 |
Six Months Ended March 31, 2025 |
Six Months Ended March 31, 2024 |
|---|---|---|---|
| Total Revenue | $124,323 | $244,199 | $254,536 |
| Operating Loss | $(2,938) | $(18,445) | $(52,487) |
| Net Loss | $(14,866) | $(42,496) | $(63,907) |
| Net Loss per Share (Diluted) | $(0.44) | $(1.39) | $(2.46) |
| Cash and Cash Equivalents | $19,299 | $19,299 | $32,695 |
| Total Debt (Net of issuance costs) | $399,540 | $399,540 | $393,339 |
| Operating Cash Flow | N/A | $(17,312) | $10,373 |
Liquidity: As of March 31, 2025, the company held $19.3 million in cash and had access to a $15.0 million revolving credit facility with no outstanding balance. However, the company reported negative operating cash flows for the six-month period.
Material Changes vs. Prior Period
- Revenue: For the six months ended March 31, 2025, total revenue decreased by 4.1% ($10.3 million) compared to the prior year. This was driven by a 4.4% decline in the Research Models and Services (RMS) segment due to lower NHP pricing and volumes, and a 3.5% decline in the Discovery and Safety Assessment (DSA) segment.
- Profitability Improvement: Despite revenue declines, the consolidated net loss improved significantly. The six-month net loss decreased from $63.9 million in 2024 to $42.5 million in 2025. This improvement was primarily due to the absence of a $26.5 million charge related to a DOJ agreement in the prior year and a $7.55 million settlement payment received from a lawsuit against Freese and Nichols, Inc. in the current period.
- Segment Performance: The RMS segment swung from an operating loss of $25.5 million in the prior six months to an operating income of $10.2 million in the current period, largely due to the non-recurring nature of the prior year's DOJ charge and the current year's settlement income.
- Inventory Build: Inventories increased significantly from $18.2 million to $38.0 million, driven by increased NHP animal research model inventory and prepaid deposits for future shipments.
Guidance, Outlook, Risks, and Unusual Items
Going Concern and Liquidity Risks
The filing explicitly states that substantial doubt exists regarding the company's ability to continue as a going concern. While management forecasts compliance with financial covenants for the next twelve months, the company has negative operating cash flows and significant debt obligations. Failure to meet covenants could trigger an event of default, potentially accelerating debt repayment which the company believes it cannot satisfy with current resources.
Debt and Covenants
- Credit Agreement: The company entered into a Seventh Amendment to its Credit Agreement in September 2024, which waived existing financial covenants until June 30, 2025, and established new tests (maximum capital expenditure limit and minimum EBITDA test) for the current period. The company was in compliance with these tests as of March 31, 2025.
- Second Lien Notes: In September 2024, the company issued $22.0 million in 15.00% Senior Secured Second Lien PIK Notes due 2027. Interest is payable in-kind, increasing the principal balance.
Unusual Items
- Settlement Income: The company received a $7.55 million settlement payment from Freese and Nichols, Inc. in March 2025, recorded as other operating income.
- DOJ Resolution: The company is subject to a Resolution Agreement and Plea Agreement with the DOJ regarding a shuttered canine breeding facility. This involves fines totaling $22.0 million payable over several years and the appointment of a Compliance Monitor for up to five years.
Outlook
Management plans to optimize capital allocation, reduce NHP revenue volatility through pre-selling inventory, and increase discovery contract awards. The company is executing "Phase Two" of its site optimization plan, expecting to complete it by March 2026 with anticipated annual savings of $6.0 million to $7.0 million.
Investor Verification Checklist
- Covenant Compliance: Verify the company's ability to meet the new Fixed Charge Coverage Ratio and Secured Leverage Ratio covenants effective June 30, 2025, given the current negative operating cash flow.
- Going Concern Status: Assess the likelihood of the company securing additional financing or achieving operational improvements sufficient to alleviate the "substantial doubt" disclosure within the next 12 months.
- NHP Supply Chain: Monitor the impact of 10% tariffs on imported non-human primates and potential supply constraints from Southeast Asia and Africa on the RMS segment's revenue stability.
- Debt Structure: Review the terms of the 15% PIK Second Lien Notes and the risk of debt acceleration if the Credit Agreement covenants are breached.
- Internal Controls: Note the disclosure of material weaknesses in internal control over financial reporting (specifically ITGCs) which remain unremediated as of March 31, 2025.